Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Receivables (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Receivables for 3 consecutive years, with $114609.0 as the latest value for Q4 2025.

  • Quarterly Receivables changed N/A to $114609.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $114609.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $1.5 million for FY2025, N/A changed from the prior year.
  • Receivables for Q4 2025 was $114609.0 at Outlook Therapeutics, down from $1.5 million in the prior quarter.
  • The five-year high for Receivables was $1.8 million in Q2 2025, with the low at $114609.0 in Q4 2025.